Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications.

ABSTRACT: Lipoprotein(a) [Lp(a)] has attracted widespread interest as a potential biomarker for cerebrovascular diseases due to its genetically determined and stable plasma concentration throughout life. Lp(a) exhibits pro-atherogenic and pro-thrombotic properties that contribute to vascular pathology in both extracranial and intracranial vessels. Elevated Lp(a) levels are strongly associated with large-artery atherosclerotic stroke, while data on its role in other ischemic subtypes and hemorrhagic stroke remains limited and inconsistent. Recent advances in Lp(a)-lowering therapies, such as antisense oligonucleotides and RNA-based agents, have demonstrated significant efficacy in reducing plasma Lp(a) levels. These advances have prompted increasing research into their potential application in the pr

SUBMITTER: Panagiotopoulos E 

PROVIDER: S-EPMC12072530 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature